Shots:
- The EC has approved Cytokinetics’ Myqorzo (5, 10, 15 & 20mg) for the treatment of adults with symptomatic (NYHA, class II-III) oHCM, with first EU launch expected in Germany by Q2’26
- Approval was based on P-III (SEQUOIA-HCM) trial of Myqorzo, showing improved exercise capacity vs PBO at 24wks., with increased peak oxygen uptake by 1.76 vs 0 ml/kg/min, consistent across all subgroups & in pts with or without background beta-blocker therapy. Results were published in The NEJM
- Myqorzo is a QD, oral cardiac myosin inhibitor that directly targets hypercontractility and LVOT obstruction associated with oHCM
Ref: Cytokinetics | Image: Cytokinetics | Press Release
Related News: Cytokinetics Launches Myqorzo in the US for Obstructive Hypertrophic Cardiomyopathy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
